Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas

作者：Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stéfania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria Chiara Tisi, Matteo Giovanni Carrabba, Ilaria Cutini, Massimo Martino, Anna Dodero, Francesca Bonifazi, Armando Santoro, Federica Sorà, Barbara Botto, Anna M. Barbui, Domenico Russo, Maurizio Musso, Giovanni Grillo, Mauro Krampera, Jacopo Olivieri, Marco Ladetto, Federica Cavallo, Massimo Massaia, Luca Arcaini, Martina Pennisi, Pier Luigi Zinzani, Rosalba Miceli, Paolo Corradini · 年份：2026 · DOI：10.1158/2643-3230.32696229 · 研究领域：CAR-T cell therapy research、Virus-based gene therapy research、Lymphoma Diagnosis and Treatment

<p>Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)</p>